Eton Pharmaceuticals (NASDAQ:ETON) Stock Lifted to “Strong-Buy” by Zacks Research

Eton Pharmaceuticals (NASDAQ:ETON) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a note issued to investors on Monday, Zacks reports.

A number of other equities research analysts have also recently commented on ETON. Craig Hallum increased their price target on shares of Eton Pharmaceuticals from $40.00 to $62.00 and gave the company a “buy” rating in a report on Tuesday, July 28th. HC Wainwright boosted their price objective on shares of Eton Pharmaceuticals from $65.00 to $70.00 and gave the stock a “buy” rating in a report on Friday, August 14th. Canaccord Genuity Group upped their price objective on Eton Pharmaceuticals from $60.00 to $68.00 and gave the company a “buy” rating in a research report on Friday, August 14th. B. Riley Financial reiterated a “buy” rating and set a $70.00 target price (up from $40.00) on shares of Eton Pharmaceuticals in a research note on Friday, August 14th. Finally, Weiss Ratings upgraded Eton Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research note on Tuesday, September 22nd. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Eton Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $67.50.

Eton Pharmaceuticals Stock Performance

Shares of ETON stock opened at $53.33 on Monday. The company has a market capitalization of $1.52 billion, a price-to-earnings ratio of 140.34 and a beta of 0.90. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.30 and a current ratio of 1.52. Eton Pharmaceuticals has a one year low of $14.27 and a one year high of $66.37. The company’s 50-day moving average is $56.13 and its 200 day moving average is $40.69.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its earnings results on Thursday, August 13th. The company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.24. The business had revenue of $37.59 million during the quarter, compared to analysts’ expectations of $27.11 million. Eton Pharmaceuticals had a net margin of 12.02% and a return on equity of 40.13%. Sell-side analysts expect that Eton Pharmaceuticals will post 1.13 EPS for the current fiscal year.

Insider Buying and Selling at Eton Pharmaceuticals

In related news, Director Paul V. Maier sold 50,000 shares of the firm’s stock in a transaction on Friday, August 28th. The stock was sold at an average price of $59.07, for a total value of $2,953,500.00. Following the transaction, the director directly owned 59,745 shares of the company’s stock, valued at approximately $3,529,137.15. This trade represents a 45.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David Krempa sold 4,166 shares of the firm’s stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $55.07, for a total value of $229,421.62. Following the completion of the transaction, the insider directly owned 43,381 shares in the company, valued at $2,388,991.67. This trade represents a 8.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 79,166 shares of company stock valued at $4,809,672 over the last 90 days. 16.49% of the stock is currently owned by company insiders.

Institutional Trading of Eton Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Toth Financial Advisory Corp bought a new stake in Eton Pharmaceuticals in the 2nd quarter worth approximately $43,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Eton Pharmaceuticals in the fourth quarter worth about $50,000. Persistent Asset Partners Ltd purchased a new position in shares of Eton Pharmaceuticals during the second quarter worth approximately $90,000. State of Wyoming purchased a new position in Eton Pharmaceuticals during the 2nd quarter worth $107,000. Finally, Quantbot Technologies LP purchased a new position in Eton Pharmaceuticals during the 2nd quarter valued at about $165,000. 27.86% of the stock is currently owned by institutional investors.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, acquiring, and commercializing treatments for rare diseases and other underserved patient populations. The company’s strategy includes advancing proprietary product candidates and obtaining rights to established medicines that can address unmet medical needs.

Eton’s portfolio has included products such as Eprontia (topiramate) oral solution for certain seizure disorders and migraine prevention, Biorphen (phenylephrine hydrochloride) injection for the treatment of clinically important hypotension, and specialty medicines used in the management of rare metabolic and endocrine conditions.